Q4 2024 |
24 |
$367M |
+$14.4M |
-$6.27M |
+$8.12M |
AMZN, GOOGL, BIO, CMPO, PCOR
|
13F-HR |
2/12/2025, 05:52 PM |
Q3 2024 |
24 |
$323M |
+$986K |
-$11.2M |
-$10.2M |
AMZN, BIO, GOOGL, CMPO, SPY
|
13F-HR |
11/12/2024, 12:23 PM |
Q2 2024 |
25 |
$283M |
+$7.03M |
-$2.16M |
+$4.87M |
AMZN, GOOGL, BIO, PCOR, GOOG
|
13F-HR |
8/12/2024, 01:13 PM |
Q1 2024 |
22 |
$318M |
+$25.3M |
-$20.7M |
+$4.59M |
AMZN, BIO, GOOGL, PCOR, SPY
|
13F-HR |
5/14/2024, 05:32 PM |
Q4 2023 |
22 |
$291M |
+$19.2M |
-$24.8M |
-$5.61M |
AMZN, BIO, GOOGL, PCOR, AVDX
|
13F-HR |
2/13/2024, 06:29 PM |
Q3 2023 |
22 |
$279M |
+$1.02M |
-$7.49M |
-$6.47M |
AMZN, BIO, GOOGL, AVDX, PCOR
|
13F-HR |
11/13/2023, 06:36 PM |
Q2 2023 |
22 |
$294M |
+$30.7M |
-$2.39M |
+$28.3M |
AMZN, BIO, GOOGL, AVDX, PCOR
|
13F-HR |
8/11/2023, 02:41 PM |
Q1 2023 |
23 |
$243M |
+$12.6M |
|
+$12.6M |
BIO, AMZN, GOOGL, AVDX, PCOR
|
13F-HR |
5/10/2023, 11:28 AM |
Q4 2022 |
23 |
$209M |
+$13.6M |
-$3.94M |
+$9.64M |
BIO, AMZN, AVDX, GOOGL, SPY
|
13F-HR |
2/6/2023, 01:47 PM |
Q3 2022 |
23 |
$216M |
+$38.5M |
|
+$38.5M |
AMZN, BIO, GOOGL, AVDX, SPY
|
13F-HR |
11/14/2022, 12:04 PM |
Q2 2022 |
24 |
$232M |
+$45M |
-$399K |
+$44.6M |
BIO, AMZN, GOOGL, AVDX, SPY
|
13F-HR |
8/12/2022, 05:56 PM |
Q1 2022 |
23 |
$313M |
+$80.7M |
|
+$80.7M |
AMZN, BIO, GOOGL, AVDX, SLGC
|
13F-HR |
5/16/2022, 02:13 PM |
Q4 2021 |
21 |
$357M |
+$72.7M |
-$1.01M |
+$71.7M |
BIOB, AMZN, GOOGL, AVDX, SPY
|
13F-HR |
2/14/2022, 09:46 AM |
Q3 2021 |
21 |
$370M |
+$45.8M |
-$50.5M |
-$4.69M |
BIOB, AMZN, INOV, GOOGL, SMRT
|
13F-HR |
11/12/2021, 11:30 AM |
Q2 2021 |
18 |
$362M |
+$83M |
-$125M |
-$42M |
AMZN, BIOB, QADA, INOV, GOOGL
|
13F-HR |
8/13/2021, 05:40 PM |
Q1 2021 |
16 |
$357M |
+$1.64M |
-$25.2M |
-$23.6M |
BIO, QADA, AMZN, INOV, GOOGL
|
13F-HR |
5/14/2021, 05:36 PM |
Q4 2020 |
17 |
$359M |
+$3.15M |
-$8.54M |
-$5.4M |
BIO, AMZN, QADA, INOV, GOOGL
|
13F-HR |
2/16/2021, 08:39 PM |
Q3 2020 |
17 |
$324M |
+$2.76M |
-$26.7M |
-$23.9M |
BIO, AMZN, QADA, INOV, FARO
|
13F-HR |
11/16/2020, 04:03 PM |
Q2 2020 |
19 |
$327M |
+$15.7M |
|
+$15.7M |
AMZN, BIO, QADA, INOV, FARO
|
13F-HR |
8/14/2020, 09:00 AM |
Q1 2020 |
17 |
$253M |
+$2.19M |
-$73M |
-$70.8M |
AMZN, BIO, QADA, INOV, FARO
|
13F-HR |
5/14/2020, 05:54 PM |
Q4 2019 |
18 |
$387M |
+$3.68M |
|
+$3.68M |
BIO, QADA, AMZN, INOV, GOOG
|
13F-HR |
2/13/2020, 12:23 PM |
Q3 2019 |
19 |
$359M |
+$9.58M |
-$4.64M |
+$4.94M |
BIO, QADA, AMZN, INOV, GOOG
|
13F-HR |
11/13/2019, 12:57 PM |
Q2 2019 |
19 |
$352M |
+$42M |
|
+$42M |
AMZN, BIO, QADA, FARO, INOV
|
13F-HR |
8/13/2019, 09:40 AM |
Q1 2019 |
19 |
$301M |
+$8.51M |
-$1.24M |
+$7.27M |
AMZN, BIO, QADA, INOV, FARO
|
13F-HR |
5/14/2019, 03:52 PM |
Q4 2018 |
20 |
$282M |
+$27.2M |
-$8.58M |
+$18.6M |
AMZN, QADA, BIO, INOV, NATI
|
13F-HR |
2/13/2019, 12:38 PM |
Q3 2018 |
19 |
$335M |
+$5.86M |
-$16.2M |
-$10.3M |
QADA, AMZN, BIO, NATI, FARO
|
13F-HR |
11/13/2018, 03:30 PM |
Q2 2018 |
18 |
$319M |
|
-$20M |
-$20M |
QADA, AMZN, BIO, NATI, FARO
|
13F-HR |
8/14/2018, 12:16 PM |
Q1 2018 |
18 |
$325M |
+$61.4M |
|
+$61.4M |
AMZN, QADA, BIO, INDA, NATI
|
13F-HR |
5/14/2018, 06:39 PM |
Q4 2017 |
18 |
$249M |
+$1.82M |
-$3.85M |
-$2.03M |
QADA, BIO, AMZN, NATI, BRKA
|
13F-HR |
2/13/2018, 05:15 PM |
Q3 2017 |
19 |
$236M |
+$15.3M |
|
+$15.3M |
QADA, BIO, AMZN, NATI, INOV
|
13F-HR |
11/13/2017, 06:11 PM |
Q2 2017 |
18 |
$212M |
+$3.99M |
-$1.94K |
+$3.99M |
QADA, BIO, AMZN, NATI, BRKA
|
13F-HR |
8/11/2017, 06:01 PM |
Q1 2017 |
17 |
$191M |
+$10.3M |
-$15.5M |
-$5.15M |
BIO, QADA, AMZN, BRKA, NATI
|
13F-HR |
5/12/2017, 01:12 PM |
Q4 2016 |
18 |
$203M |
+$6.11M |
-$7.71M |
-$1.6M |
QADA, BIO, SPY, AMZN, BRKA
|
13F-HR |
2/13/2017, 10:35 AM |
Q3 2016 |
18 |
$192M |
+$18.7M |
|
+$18.7M |
QADA, BIO, AMZN, SPY, NATI
|
13F-HR |
11/14/2016, 08:44 AM |
Q2 2016 |
17 |
$171M |
+$2.31M |
-$7.94K |
+$2.3M |
SPY, QADA, BIO, AMZN, NATI
|
13F-HR |
8/15/2016, 11:04 AM |
Q1 2016 |
16 |
$180M |
+$12.7M |
-$6.07M |
+$6.67M |
QADA, SPY, NATI, BIO, AMZN
|
13F-HR |
5/16/2016, 11:12 AM |
Q4 2015 |
18 |
$191M |
+$32.9M |
|
+$32.9M |
SPY, QADA, NATI, BIO, AMZN
|
13F-HR |
2/16/2016, 09:57 AM |
Q3 2015 |
19 |
$180M |
+$2.86M |
-$4.62M |
-$1.75M |
QADA, SPY, NATI, BIO, AMZN
|
13F-HR |
11/16/2015, 08:58 AM |
Q2 2015 |
19 |
$189M |
+$7.07M |
-$4.89M |
+$2.18M |
SPY, QADA, NATI, BIO, NICE
|
13F-HR |
8/14/2015, 10:57 AM |
Q1 2015 |
19 |
$181M |
+$35.1M |
-$6.72M |
+$28.4M |
SPY, QADA, NATI, BRKA, NICE
|
13F-HR |
5/15/2015, 11:00 AM |
Q4 2014 |
16 |
$153M |
+$16M |
-$224K |
+$15.8M |
SPY, BRKA, NATI, NICE, BIO
|
13F-HR |
2/17/2015, 09:06 AM |
Q3 2014 |
16 |
$131M |
+$939K |
-$159K |
+$780K |
SPY, BRKA, NATI, BAC, GS
|
Restatement |
11/21/2014, 08:43 AM |
Q2 2014 |
17 |
$142M |
+$21.5M |
-$54.2K |
+$21.4M |
SPY, NATI, BRKA, BIOB, NICE
|
13F-HR |
8/14/2014, 11:03 AM |
Q1 2014 |
17 |
$135M |
|
|
|
SPY, BRKA, BIO, NATI, BAC
|
13F-HR |
5/15/2014, 11:00 AM |